These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29414040)

  • 1. Identification and characterization of the druggable kinase targets of olmesartan and its analogues from a systematic kinase-chemical interaction profile in atherosclerosis.
    Zhuang RJ; Jin WD; Wang XY; Wu XM
    J Mol Graph Model; 2018 Mar; 80():211-216. PubMed ID: 29414040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic identification of the druggable interactions between human protein kinases and naturally occurring compounds in endometriosis.
    Jiang L; Tang C; Rao J; Xue Q; Wu H; Wu D; Zhang A; Chen L; Shen Z; Lei L
    Comput Biol Chem; 2017 Dec; 71():136-143. PubMed ID: 29096379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse in silico-in vitro fishing of unexpected paroxetine kinase targets from tumor druggable kinome.
    Zhou W; Yang H; Wang H
    J Mol Model; 2020 Jul; 26(8):197. PubMed ID: 32623519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
    Sada T; Mizuno M
    Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):257-69. PubMed ID: 15467259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
    Takai S; Miyazaki M
    Am J Cardiovasc Drugs; 2006; 6(6):363-6. PubMed ID: 17192125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
    Gardner SF; Franks AM
    Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational creation and systematic analysis of cervical cancer kinase-inhibitor binding profile.
    Han M; Sun D
    J Comput Aided Mol Des; 2019 Jul; 33(7):689-698. PubMed ID: 31203490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olmesartan inhibits angiotensin II-Induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways.
    Kyotani Y; Zhao J; Tomita S; Nakayama H; Isosaki M; Uno M; Yoshizumi M
    J Pharmacol Sci; 2010; 113(2):161-8. PubMed ID: 20508392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine.
    Ishizuka T; Fujimori I; Kato M; Noji-Sakikawa C; Saito M; Yoshigae Y; Kubota K; Kurihara A; Izumi T; Ikeda T; Okazaki O
    J Biol Chem; 2010 Apr; 285(16):11892-902. PubMed ID: 20177059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.
    Le MT; Pugsley MK; Vauquelin G; Van Liefde I
    Br J Pharmacol; 2007 Aug; 151(7):952-62. PubMed ID: 17572702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker.
    Mire DE; Silfani TN; Pugsley MK
    J Cardiovasc Pharmacol; 2005 Nov; 46(5):585-93. PubMed ID: 16220064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olmesartan medoxomil.
    Warner GT; Jarvis B
    Drugs; 2002; 62(9):1345-53; discussion 1354-6. PubMed ID: 12076183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels.
    Zhu LX; Liu Q; Hua YF; Yang N; Zhang XG; Ding X
    Comput Biol Chem; 2019 Jun; 80():324-332. PubMed ID: 31078911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
    Brunner HR
    J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.
    Ram CV
    Curr Med Res Opin; 2009 Jan; 25(1):177-85. PubMed ID: 19210150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.
    Shimada K; Murayama T; Yokode M; Kita T; Fujita M; Kishimoto C
    Nutr Metab Cardiovasc Dis; 2011 Sep; 21(9):672-8. PubMed ID: 20399087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olmesartan medoxomil: current status of its use in monotherapy.
    Brunner HR
    Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
    Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK
    Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A novel synthesis of olmesartan medoxomil and examination of its related impurities].
    Wu TZ; Liu XH; Zhang FL; Xie MH
    Yao Xue Xue Bao; 2006 Jun; 41(6):537-43. PubMed ID: 16927829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.